Francesc Balaguer, Head of the Gastroenterology Department at Hospital Clinic de Barcelona, posted on LinkedIn:
“We are proud to announce a major milestone in cancer prevention for Lynchsyndrome.
The first patient has been vaccinated in our Phase 1 trial with an autologous dendritic cell vaccine loaded with Lynch-specific neo-peptides.
Lynch syndrome is the most common hereditary cause of colorectal and endometrial cancer. In these syndrome, inherited DNA mismatch‐repair mutations create characteristic mutant ‘neoantigens’ (frameshift neopeptides) that can be recognized by T cells.
This innovative strategy aims to harness the immune system to recognize and eliminate precancerous cells before tumors develop.
This achievement has been possible thanks to the dedication of Daniel Benitez Ribas, Cristina Bayó, Joaquín Castillo, Manel Juan, Maria Pellise Urquiza, Teresa Ocaña, Leticia Moreira, Antoni Castells Garangou, Sabela Carballal Ramil, Maria Daca Alvarez, Georgina Flórez-Grau, Liseth Rivero-Sánchez, Oswaldo Ortiz Zuñiga, Hardeep Kumari, and many more at Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), with the support of AFALynch.”
More from Francesc Balaguer on OncoDaily.